Molecular diagnostics of colorectal cancer

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 5, 2011, Pages 578-587

  Bedeir, Ahmed ^a   Krasinskas, Alyssa M ^b  

^a CARIS LIFE SCIENCES   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; COLORECTAL TUMOR; GENETICS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MEDLINE; METABOLISM; METHODOLOGY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOLECULAR DIAGNOSIS; POINT MUTATION;

ADENOCARCINOMA; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MOLECULAR DIAGNOSTIC TECHNIQUES; POINT MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PUBMED; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 79956359425     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Malkhosyan S, Rampino N, Yamamoto H, Perucho M. Frameshift mutator mutations. Nature. 1996, 382(6591):499-500.
2. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995; 268 (5215): 1336-1338.
3. Rampino N, Yamamoto H, lonov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 1997; 275 (5302): 967-969. (Pubitemid 27087710)
4. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med. 2003;138(7):560-570.
5. Marra G, Schar P. Recognition of DNA alterations by the mismatch repair system. Biochem J. 1999;338(pt 1):1-13. (Pubitemid 29097278)
6. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005; 352(18):1851-1860.
7. Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2000; 18(11):2193-2200. (Pubitemid 30350210)
8. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer.; Med Genet. 1999; 36(11):801-818. (Pubitemid 29520569)
9. Peltomäki P, Vasen H. Mutations associated with HNPCC predispositionupdate of ICG-HNPCC/INSiGHT mutation database. Dis Markers. 2004;20(4-5): 269-276. (Pubitemid 40164099)
10. Vasen HF, Wijnen JT, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology. 1996; 110(4): 1020-1027. (Pubitemid 26113739)
11. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology. 1999; 116(6): 1453-1456. (Pubitemid 29258894)
12. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer. 1993; 71(3):677-685. (Pubitemid 23051366)
13. Hemminki A, Peltomäki P, Mecklin JP, et al. Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer. Nat Genet. 1994; 8(4):405-410.
14. Lazar V, Grandjouan S, Bognel C, et al. Accumulation of multiple mutations in tumour suppressor genes during colorectal tumorigenesis in HNPCC patients. Hum Mol Genet 1994; 3(12): 2257-2260.
15. Lynch HT, Drouhard TJ, Schuelke GS, Biscone KA, Lynch JF, Danes BS. Hereditary nonpolyposis colorectal cancer in a Navajo Indian family. Cancer Genet Cytogenet. 1985; 15(3-4): 209-213. (Pubitemid 15140843)
16. Mecklin JP, Sipponen P, Jarvinen HJ. Histopathology of colorectal carcinomas and adenomas in cancer family syndrome. Dis Colon Rectum. 1986, 29(12):849-853. (Pubitemid 17208885)
17. Halvarsson B, Lindblom A, Johansson L, Lagerstedt K, Nilbert M. Loss of mismatch repair protein immunostaining in colorectal adenomas from patients with hereditary nonpolyposis colorectal cancer. Mod Pathol. 2005;18(81:1095-1101.
18. Vasen HF, Nagengast FM, Khan PM. Interval cancers in hereditary nonpolyposis colorectal cancer (Lynch syndrome). Lancet. 1995; 345(8958):1183- 1184.
19. Jenkins MA, Hayashi S, O'Shea AM, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology. 2007;133(1):48-56. (Pubitemid 47039240)
20. Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol. 1994:145(1):148-156. (Pubitemid 24217493)
21. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998; 95(12):6870-6875. (Pubitemid 28278073)
22. Kane MF, Loda M, Gaida GM, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997;57(5):808-811. (Pubitemid 27097998)
23. lonov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993; 363(6429):558-561.
24. Snover DC, Jass JR, Fenoglio-Preiser C, Batts KP. Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept. Am J Clin Pathol. 2005; 124(3):380-391. (Pubitemid 41232924)
25. Ahuja N, Mohan AL, Li Q, et al. Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res. 1997; 57(16): 3370-3374. (Pubitemid 27355477)
26. Domingo E, Laiho P, Ollikainen M, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet. 2004; 41(9): 664-668. (Pubitemid 39208606)
27. Loughrey MB, Waring PM, Tan A, et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary nonpolyposis colorectal cancer. Fam Cancer. 2007; 6(3): 301-310. (Pubitemid 47175009)
28. Jass JR, Smyrk TC, Stewart SM, Lane MR, Lanspa SJ, Lynch HT. Pathology of hereditary non-polyposis colorectal cancer. Anticancer Res. 1994;14(4B): 1631-1634. (Pubitemid 24356996)
29. Yearsley M, Hampel H, Lehman A, Nakagawa H, de la Chapelle A, Frankel WL. Histologic features distinguish microsatellite-high from microsatellite-low and microsatellite-stable colorectal carcinomas, but do not differentiate germline mutations from methylation of the MLH1 promoter. Hum Pathol. 2006; 37(71:831-838.
30. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58(22):5248-5257.
31. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004; 96(4):261-268. (Pubitemid 38256271)
32. Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 2002;20(4): 1043-1048. (Pubitemid 34141849)
33. Marcus VA, Madlensky L, Gryfe R, et al. Immunohistochemistry for hMLHI and hMSH2: a practical test for DNA mismatch repair-deficient tumors. Am J Surg Pathol. 1999; 23(10):1248-1255. (Pubitemid 29474595)
34. Thibodeau SN, French AJ, Roche PC, et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res. 1996; 56(21):4836-4840. (Pubitemid 26374414)
35. Abdel-Rahman WM, Mecklin JP, Peltomäki P. The genetics of HNPCC: application to diagnosis and screening. Crit Rev Oncol Hematol. 2006;58(3): 208-220. (Pubitemid 43796078)
36. Lagerstedt Robinson K, Liu T, Vandrovcova J, et al. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst. 2007; 99(4):291-299. (Pubitemid 47073492)
37. de Jong AE, van Puijenbroek M, Hendriks Y, et al. Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004;10(3):972-980. (Pubitemid 38198898)
38. Hall G, Clarkson A, Shi A, et al. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma. Pathology. 2010; 42(5):409-413.
39. Shia J, Tang LH, Vakiani E, et al. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol. 2009.
40. Southey MC, Jenkins MA, Mead L, et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol. 2005; 23(27): 6524-6532. (Pubitemid 46190244)
41. Barnetson RA, Tenesa A, Fartington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med. 2006; 354(26): 2751-2763. (Pubitemid 43974193)
42. Suraweera N, Ďuval A, Reperant M, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology. 2002;123(6):1804-1811. (Pubitemid 35408304)
43. Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome, part II: the utility of microsatellite instability testing. J Mol Diagn. 2008; 10(4):301-307. (Pubitemid 352019114)
44. Deschoolmeester V, Baay M, Wuyts W, et al. Detection of microsatellite instability in colorectal cancer using an alternative multiplex assay of quasimonomorphic mononucleotide markers. J Mol Diagn. 2008; 10(2):154-159. (Pubitemid 351436269)
45. Bellizzi AM, Frankel WL. Colorectal cancer due to deficiency in DNA mismatch repair function: a review. Adv Anat Pathol. 2009; 16(6): 405-417.
46. Vasen HF, Moslem G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet. 2007; 44(6): 353-362. (Pubitemid 46953715)
47. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst. 1997;89(23): 1758-1762.
48. Samowitz WS, Curtin K, Ma KN, et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev. 2001; 10(9):917-923. (Pubitemid 32844897)
49. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001,-344(16): 1196-1206.
50. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58(1):90-96.
51. Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology. 2004; 126(2):394-401. (Pubitemid 38182296)
52. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003; 349(3):247-257. (Pubitemid 36859476)
53. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICGHNPCC). Dis Colon Rectum. 1991; 34(5):424-425.
54. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998; 338(21):1481-1487. (Pubitemid 28226275)
55. Cunningham JM, Kim CY, Christensen ER, et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet. 2001;69(4):780-790. (Pubitemid 32868523)
56. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008, 26(35): 5783-5788.
57. Julie C, Tresallet C, Brouquet A, et al. Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening [quiz in Am J Gastroenterol. 2008;103(11):2836]. Am J Gastroenterol. 2008; 103(11): 2825-2835.
58. Berg AO. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009; 11(1): 35-41.
59. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase Il trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004; 22(7): 1201-1208. (Pubitemid 41079832)
60. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(10): 1626-1634.
61. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19(3):508-515. (Pubitemid 351325672)
62. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 2007; 96(8): 1166-1169. (Pubitemid 46625066)
63. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359(17): 1757-1765.
64. Lievre A, Sachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.; Clin Oncol. 2008; 26(3): 374-379. (Pubitemid 351171687)
65. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8): 3992-3995.
66. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009; 27(12): 2091-2096.
67. Members NCCP. NCCN Clinical Practice Guidelines in Oncology-Colon Cancer. In: Network NCC, eds. Vol 4. Fort Washington, PA: NCCN publication; 2008.
68. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev. 2000; 9(11):1193-1197.
69. Brink M, de Goeij AF, Weijenberg MP, et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis. 2003; 24(4): 703-710. (Pubitemid 36592405)
70. Monzon FA, Ogino S, Hammond ME, Hailing KC, Bloom KJ, Nikiforova MN. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med. 2009; 133(10):1600-1606.
71. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26(35):5705-5712.
72. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009,101 (41:715-721.
73. Edkins S, O'Meara S, Parker A, et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther. 2006;5(8):928-932.
74. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11(8): 753-762.
75. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer. 2007; 97(8):1139-1145. (Pubitemid 47587019)
76. Perrone F, Lampis A, Orsenigo M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol. 2009; 20(1):84-90.
77. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002; 418 (6901):934. (Pubitemid 34976022)
78. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 2004; 6(4):313-319. (Pubitemid 39361432)
79. Spano JP, Fagard R, Soria JC, Rixe O, Khayat D, Milano G. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol. 2005;16(2):189-194. (Pubitemid 40309295)